- In late June 2026, Boston Scientific was removed from several Russell growth indexes and initiated a Class II recall of 9,750 Orca single-use air/water and suction valves in the US after reports of suction buttons sticking.
- At the same time, analysts expressed concern about slowing growth in the company’s Watchman heart device franchise, even as promising clinical data helped support confidence in Boston Scientific’s broader pipeline and long-term prospects.
- We’ll now examine how concerns around Watchman’s slower growth alter Boston Scientific’s existing investment narrative built on innovation and expanding margins.
The future of work is here. Discover the 30 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
Boston Scientific Investment Narrative Recap
To own Boston Scientific today, you have to believe its broad cardiology and MedSurg portfolios, including FARAPULSE and Watchman, can keep driving profitable growth despite recent setbacks. Near term, the key catalyst is execution in electrophysiology and structural heart, while the biggest current risk is that slower Watchman growth and any further product quality issues could weigh on sentiment and margins. The Russell index removals and Orca valve recall do not appear financially material on their own.
Among recent announcements, the US$1.5 billion investment for a 34% stake in MiRus, with an option to acquire its TAVR system, stands out. It underscores Boston Scientific’s push to reinforce its structural heart pipeline at a time when Watchman faces growth concerns and analysts are reassessing utilization and valuation risks. For investors, MiRus adds another potential long term growth driver, but also raises the execution and integration bar if growth in existing franchises slows.
Yet behind the product recalls and Watchman concerns, there is a quieter risk investors should be aware of around potential reimbursement shifts and...
Read the full narrative on Boston Scientific (it's free!)
Boston Scientific's narrative projects $25.8 billion revenue and $4.8 billion earnings by 2029.
Uncover how Boston Scientific's forecasts yield a $75.00 fair value, a 66% upside to its current price.
Exploring Other Perspectives
Before this news, the most optimistic analysts were assuming revenue could reach about US$28.0 billion and earnings US$6.0 billion by 2029, which contrasts sharply with the current worries about Watchman’s slowdown and shows how far opinions can differ and may need to be revisited as new information emerges.
Explore 8 other fair value estimates on Boston Scientific - why the stock might be worth just $75.00!
Form Your Own Verdict
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Boston Scientific research is our analysis highlighting 4 key rewards that could impact your investment decision.
- Our free Boston Scientific research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Boston Scientific's overall financial health at a glance.
Searching For A Fresh Perspective?
Opportunities like this don't last. These are today's most promising picks. Check them out now:
- Find 44 companies with promising cash flow potential yet trading below their fair value.
- Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
- Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 30 best rare earth metal stocks of the very few that mine this essential strategic resource.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com